Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration

Ann Rheum Dis. 2024 Nov 12:ard-2024-226772. doi: 10.1136/ard-2024-226772. Online ahead of print.

FOREUM Boot Camp Working Group member:
Johannes Wj Bijlsma, Iain McInnes, Kenneth Baker, Rik Lories, Costantino Pitzalis, Jörg Hw Distler, Gerd Burmester, Andrew P Cope, Oliver Distler, Julia Spierings, Anna Maria Hoffmann-Vold, Tim Radstake, Christian A Goess, Lauren Reinke-Breen, Bernard Lauwerys, Danielle M Gerlag, Emma Smith, Ruchi Singh, Roberta Weiss, Martin Hegen, Martin Brom, Stephen Oliver, Richard Vesely

¹ Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
² Rheumatology Department, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
³ Rheumatology and Clinical Immunology, Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands.
⁴ Novartis, Basel, Switzerland.
⁵ AbbVie Inc, Cambridge, Massachusetts, USA.
⁶ UCB, Slough, UK.
⁷ Pfizer, Collegeville, Pennsylvania, USA.
⁸ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany gerd.burmester@charite.de.

No abstract available

Keywords: rheumatoid arthritis; scleroderma, systemic; treatment.